NASDAQ · GLSI
Healthcare · Biotechnology
$16.98
Down-$0.37 (-2.13%)
Updated Oct 3, 2026, 6:28 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GLSI
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
GLSI closed at $16.98 after 20 trading sessions, up 6.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $17.65 | $18.25 | $16.60 | $16.98 | 175.42K |
| Oct 1, 2026 | $18.12 | $18.35 | $16.81 | $17.35 | 121.61K |
| Sep 30, 2026 | $18.60 | $19.31 | $18.01 | $18.05 | 145.1K |
| Sep 29, 2026 | $18.78 | $19.21 | $18.20 | $18.38 | 65.83K |
| Sep 28, 2026 | $18.12 | $19.00 | $17.85 | $18.59 | 82.97K |
| Sep 25, 2026 | $18.00 | $18.685 | $18.00 | $18.22 | 67.13K |
| Sep 24, 2026 | $17.46 | $18.15 | $17.30 | $18.10 | 88.14K |
| Sep 23, 2026 | $19.31 | $19.36 | $17.12 | $17.51 | 187.14K |
| Sep 22, 2026 | $18.58 | $20.3084 | $18.31 | $19.48 | 122.88K |
| Sep 21, 2026 | $19.20 | $19.24 | $18.12 | $18.595 | 110.28K |
| Sep 18, 2026 | $18.40 | $20.038 | $18.25 | $18.99 | 302.26K |
| Sep 17, 2026 | $16.04 | $18.75 | $16.04 | $18.39 | 246.98K |
| Sep 16, 2026 | $16.09 | $16.37 | $15.3468 | $15.63 | 121.66K |
| Sep 15, 2026 | $15.81 | $16.43 | $15.35 | $16.09 | 96.84K |
| Sep 14, 2026 | $15.15 | $16.30 | $15.15 | $16.05 | 100.23K |
| Sep 11, 2026 | $15.33 | $15.595 | $15.09 | $15.45 | 75K |
| Sep 10, 2026 | $14.54 | $15.345 | $14.46 | $15.06 | 68.52K |
| Sep 9, 2026 | $15.79 | $16.34 | $14.90 | $15.03 | 103.34K |
| Sep 8, 2026 | $15.71 | $16.25 | $15.53 | $15.90 | 63.06K |
| Sep 4, 2026 | $15.45 | $15.98 | $15.45 | $15.95 | 65.12K |
The latest Smart Investors Daily articles mentioning GLSI.
Company
Market Activity
Research & News
GLSI research
Company profile and research snapshot.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 30, 2026
STAFFORD, Texas, April 30, 2026 -- Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track...
Benzinga · Mar 19, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga · Mar 18, 2026
Benzinga · Mar 17, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLSI.
